Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.